Summary:
Biofidelity is launching Enspyre, a novel target enrichment technology that significantly enhances next-generation sequencing (NGS) efficiency by selectively removing background DNA, improving sensitivity, reducing costs, and enabling new clinical and research applications.
Takeaways:
- Enhanced NGS Efficiency – Enspyre removes up to 99% of background DNA, dramatically improving signal-to-noise ratio and sequencing depth.
- Broad Applications – The technology has potential uses in oncology, including MRD testing, and reduces data processing time and storage needs.
- Strategic Commercialization – Biofidelity is pursuing partnerships to integrate Enspyre into global pharmaceutical and precision medicine markets.
Biofidelity, a provider of genomic solutions, will present launch details for Enspyre, a novel target enrichment technology with a broad spectrum of potential applications that allows for selective enrichment of specified variants prior to sequencing.
“NGS is highly inefficient—with as few as one in 20 million sequenced bases resulting in a variant call. This results in poor signal to noise, severely limiting the potential of NGS that even AI will never unlock,” says Biofidelity Co-founder and CEO Barnaby Balmforth, PhD. “Enspyre removes up to 99% of background DNA prior to sequencing, enabling high throughput NGS applications on benchtop sequencers. This cracks wide open the potential for new applications of NGS across clinical use and research science.”
Biofidelity Redefines NGS
Enspyre (enrichment by selective pyrophosphorolysis and release) redefines what is possible with NGS by dramatically enhancing signal to noise, enabling the identification of variants with a sequencing depth reduced by more than 95% compared to a non-selective assay. This presents the opportunity to transform a broad spectrum of potential applications within oncology, including minimum residual disease (MRD) testing, and beyond. Additional benefits include lower data processing time and significantly decreased data storage requirements. Cumulatively, these benefits could significantly improve sensitivity, bring down the cost of sequencing necessary for MRD detection, and deliver results significantly faster for patients.
Biofidelity will present Enspyre proof of concept data at the Advances in Genome Biology and Technology (AGBT) General Meeting, in a poster titled: Enspyre: A novel enrichment technology for selected DNA variants using pyrophosphorolysis.
Enspyre Complementary fo Aspyre
Enspyre technology is complementary to Biofidelity’s PCR-based Aspyre technology and the commercially available Aspyre Lung product which enables fast, simple, decentralized testing for non-small cell lung cancer biomarkers in tissue and blood. Together, these two technologies enable a pipeline of products to be purpose-built to meet critical unmet needs throughout oncology.
Biofidelity is taking an ‘Intel Inside’ approach to making Enspyre commercially available. The company is actively pursuing partnering and licensing opportunities with multiple global pharmaceutical companies, contract research organizations (CROs) and precision medicine drug developers.
Featured Image: Enspyre is a novel target enrichment technology with a broad spectrum of potential applications that allows for selective enrichment of specified variants prior to sequencing. Photo: Biofidelity
